Klaria Pharma Plans Potential US Launch of Migraine Treatment With Partner

• Klaria Pharma has finalized a strategy for a potential US launch of Sumatriptan Alginatfilm with a partner.
• The BDO-led process targets licensing deals outside Europe or transactions involving most or all assets; no timetable has been set.
• Partner CNX Therapeutics plans an imminent European launch, targeting 10-30% of the region’s approximately SEK 1 billion annual sumatriptan market.
• The European agreement provides milestone payments and double-digit sales royalties, with significant revenue expected over the next 12 months.
• A small tolerability study remains before a US registration application, potentially using US participants or European patients following launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.